Charles Schwab Investment Management Inc. Grows Position in Repligen Co. (NASDAQ:RGEN)

Charles Schwab Investment Management Inc. lifted its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 4.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 377,900 shares of the biotechnology company’s stock after buying an additional 14,521 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.67% of Repligen worth $54,395,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Atria Investments Inc boosted its position in Repligen by 67.9% in the third quarter. Atria Investments Inc now owns 3,202 shares of the biotechnology company’s stock worth $477,000 after purchasing an additional 1,295 shares during the last quarter. Crossmark Global Holdings Inc. boosted its position in Repligen by 12.0% in the third quarter. Crossmark Global Holdings Inc. now owns 4,068 shares of the biotechnology company’s stock worth $606,000 after purchasing an additional 436 shares during the last quarter. State of New Jersey Common Pension Fund D boosted its position in Repligen by 2.0% in the third quarter. State of New Jersey Common Pension Fund D now owns 19,700 shares of the biotechnology company’s stock worth $2,932,000 after purchasing an additional 382 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Repligen in the third quarter worth about $306,000. Finally, Venturi Wealth Management LLC raised its stake in shares of Repligen by 28.1% in the third quarter. Venturi Wealth Management LLC now owns 1,369 shares of the biotechnology company’s stock worth $204,000 after buying an additional 300 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Price Performance

RGEN opened at $142.44 on Friday. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $200.23. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The business’s fifty day simple moving average is $157.17 and its 200-day simple moving average is $148.45. The company has a market capitalization of $7.98 billion, a price-to-earnings ratio of -279.29, a PEG ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. On average, equities research analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock. TD Cowen started coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective on the stock. Wolfe Research initiated coverage on Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $180.00 price objective on shares of Repligen in a research note on Friday, February 21st. Finally, Canaccord Genuity Group lifted their price objective on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Repligen has a consensus rating of “Moderate Buy” and a consensus price target of $181.00.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.